Assay News and Research

RSS

Cannabis plant may harbor SARS-CoV-2 for at least a week

Researchers at the Medicinal Genomics Corporation have warned that cannabis flowers exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may harbor the virus for at least seven days.

14 Jun 2020

NIAID and Moderna scientists describe SARS-CoV-2 vaccine development

Researchers at the National Institute of Allergy and Infectious Diseases and Moderna Inc., have described the potent neutralizing effects of a candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is currently being tested in a phase II trial.

14 Jun 2020

Study reveals protein responsible for vulnerability in cancer cells

A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

14 Jun 2020

PCR Biosystems launches new kit for ultra-sensitive, high-throughput detection of SARS-CoV-2

PCR Biosystems, the UK-based PCR experts, today announced the launch of qPCRBIO Probe 1-Step Virus Detect, a high-concentration 4x RT-qPCR kit designed specifically for ultra-sensitive, high-throughput detection of viral RNA sequences, including SARS-CoV-2.

12 Jun 2020

UNC scientists develop new kind of antibody test for COVID-19

As the COVID-19 pandemic continues with many thousands of new infections reported each day, there is a need for widely applicable surveillance testing to gain a better understanding of infection rates, especially the number of infections in people with mild or no symptoms, who can still be carriers.

11 Jun 2020

Synthetic nanobodies potent neutralizers for SARS-CoV-2

Researchers at the Chinese Academy of Sciences report the generation of potent synthetic nanobodies that selectively and efficiently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus.

11 Jun 2020

Treatment with vitamin A analog improves visual function in diabetic mice

Diabetic retinopathy is a common complication of diabetes and a leading cause of blindness among the working-age population.

11 Jun 2020

Rapid point-of-care testing using screen-printed electrodes from Metrohm DropSens

Point-of-care testing with screen-printed electrodes allows rapid testing of populations for viral outbreaks – at affordable costs, without the need for trained specialists and/or complicated equipment.

From Metrohm USA Inc. 11 Jun 2020

Scientists investigate immune responses to SARS-CoV-2 spike immunogens

The coronavirus pandemic is actively spreading across the globe, with millions of people infected. Amid the global health crisis, scientists race to develop an effective vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

10 Jun 2020

Seroprevalence of IgM and IgG against SARS-CoV-2 in China

A new study published in the journal Nature Medicine in June 2020 reports the seroprevalence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across China. This may help to understand the actual prevalence of the virus in the current pandemic.

10 Jun 2020

QuantuMDx receives CE-IVD marking for SARS-CoV-2 detection assay

QuantuMDx Group Limited, a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today announces its SARS-CoV-2 detection assay has been CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within the European Union.

10 Jun 2020

Research demonstrates novel pathway regulating the underlying mechanism of NASH

CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems that improve the accuracy and efficiency of drug discovery, today announced the publication of co-authored research led by researchers at the University of Cambridge in Nature Metabolism, identifying a novel pathway that regulates the underlying mechanism of Non-Alcoholic Steatohepatitis, potentially a new therapeutic target.

10 Jun 2020

G42 and Oxford Nanopore co-develop population-scale technology to detect SARS-CoV-2

Group 42 (G42), a leading AI and Cloud Computing company based in the United Arab Emirates, and Oxford Nanopore Technologies, an advanced sequencing technology company based in the United Kingdom, announced today they have developed an unprecedented population-scale technology that rapidly and accurately detects SARS-CoV-2, the virus that causes COVID-19.

10 Jun 2020

Coronavirus (COVID-19) sample tracking packages

To assist labs involved with the essential RT-PCR assay part of the “test, trace and isolate” strategy for dealing with the SARS-CoV-2 virus pandemic – Ziath has introduced two optimized packages for reliable tracking of patient samples submitted for Coronavirus (COVID-19) testing.

From Ziath Ltd 10 Jun 2020

Deep UV LED inactivation of SARS-CoV-2 - fast and effective

The ongoing pandemic has aroused considerable effort to find methods to prevent and control the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19 disease. Rapid inactivation devices would be of great help in this area, to prevent viral transmission through aerosols and contact with infected surfaces.

9 Jun 2020

Avacta provides update on COVID-19 antigen diagnostic test development with Adeptrix

Avacta Group plc is pleased to announce that a BAMS™ diagnostic test for COVID-19, being developed with Adeptrix, has reached the prototype stage.

From Avacta Life Sciences Ltd. 9 Jun 2020

Anti-RBD antibodies shown to neutralize active SARS-CoV-2

A new study published on the preprint server bioRxiv* in June 2020 reports the discovery of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in samples from healthy donors, collected before the pandemic. These antibodies are capable of inhibiting the binding of the spike protein of the virus to the angiotensin-converting enzyme 2 (ACE2) molecule and can neutralize active infection of cells in culture.

9 Jun 2020

Synthetic monoclonal antibodies effectively neutralize SARS-CoV-2 in laboratory conditions

In a new study available on the preprint server bioRxiv*, a multinational research group demonstrated how monoclonal antibodies strongly inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro at even sub-nanomolar concentrations. This makes them a prime candidate for the treatment of coronavirus disease (COVID-19).

8 Jun 2020

Improving detection of SARS-CoV-2 infection among severely ill children

Researchers in the UK have conducted a study showing that children with a severe inflammatory syndrome had high levels of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), despite having tested negative for the virus by polymerase chain reaction (PCR).

8 Jun 2020

New EUbOPEN consortium will enable access to research tools to unlock disease biology

Frankfurt and Ingelheim. Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete.

8 Jun 2020

Assay News and Research

Cannabis plant may harbor SARS-CoV-2 for at least a week

NIAID and Moderna scientists describe SARS-CoV-2 vaccine development

Study reveals protein responsible for vulnerability in cancer cells

PCR Biosystems launches new kit for ultra-sensitive, high-throughput detection of SARS-CoV-2

UNC scientists develop new kind of antibody test for COVID-19

Synthetic nanobodies potent neutralizers for SARS-CoV-2

Treatment with vitamin A analog improves visual function in diabetic mice

Rapid point-of-care testing using screen-printed electrodes from Metrohm DropSens

Scientists investigate immune responses to SARS-CoV-2 spike immunogens

Seroprevalence of IgM and IgG against SARS-CoV-2 in China

QuantuMDx receives CE-IVD marking for SARS-CoV-2 detection assay

Research demonstrates novel pathway regulating the underlying mechanism of NASH

G42 and Oxford Nanopore co-develop population-scale technology to detect SARS-CoV-2

Coronavirus (COVID-19) sample tracking packages

Deep UV LED inactivation of SARS-CoV-2 - fast and effective

Avacta provides update on COVID-19 antigen diagnostic test development with Adeptrix

Anti-RBD antibodies shown to neutralize active SARS-CoV-2

Synthetic monoclonal antibodies effectively neutralize SARS-CoV-2 in laboratory conditions

Improving detection of SARS-CoV-2 infection among severely ill children

New EUbOPEN consortium will enable access to research tools to unlock disease biology

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News